Researchers Detail New Data on Disease Progression in Colorectal Cancer

Strategic Insights -

Researchers at Ludwig-Maximilians-University Munich have evaluated the distribution and risk of disease progression in first-line therapy of unresected metastatic colorectal cancer patients. The study analyzed data from 11 clinical trials to provide guidance for the timing of disease reassessments during first-line therapy.

Key Takeaways:

  • The maximum frequency of disease progression events was observed at 7.6 months, with an absolute disease progression risk of 19% in the overall population.
  • In RAS/BRAF wild-type patients, the maximum disease progression risk was 23% at 14 months, while in RAS mutant patients, it was 25% at 10 months, and in BRAF mutant patients, it was 35% at 8 months.
  • Baseline characteristics such as ECOG-PS 0, right sidedness, initially unresected primary tumor, higher number of organs involved by metastases, and BRAF mutation were independently associated with higher risk of disease progression in first-line therapy.
  • Early tumor shrinkage (ETS) significantly mitigated the impact of baseline characteristics on progression-free survival (PFS) in the model.
  • The distribution of disease progression events was non-Gaussian, with the highest density observed between the third and fourth reassessment of a bimonthly surveillance schedule.

Statistics:

  • 2939 unresected patients from 11 clinical trials were analyzed.
  • The maximum frequency of disease progression events was observed at 7.6 months.
  • The absolute disease progression risk was 19% in the overall population.
  • The maximum disease progression risk in RAS/BRAF wild-type patients was 23% at 14 months.
  • The maximum disease progression risk in RAS mutant patients was 25% at 10 months.
  • The maximum disease progression risk in BRAF mutant patients was 35% at 8 months.

Sources:

  • AIO and GONO, "Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials"
  • Annals of Oncology, Volume 2025
  • Ludwig-Maximilians-University Munich, "Researchers at Ludwig-Maximilians-University Munich Release New Data on Disease Progression"
  • NewsRx LLC, "Researchers at Ludwig-Maximilians-University Munich Release New Data on Disease Progression"